Research Papers:

Suppression of skin tumorigenesis in CD109-deficient mice

Masaki Sunagawa, Shinji Mii, Atsushi Enomoto, Takuya Kato, Yoshiki Murakumo, Yukihiro Shiraki, Naoya Asai, Masato Asai, Masato Nagino and Masahide Takahashi _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:82836-82850. https://doi.org/10.18632/oncotarget.12653

Metrics: PDF 853 views  |   HTML 1194 views  |   ?  


Masaki Sunagawa1,2, Shinji Mii1,3, Atsushi Enomoto1, Takuya Kato4, Yoshiki Murakumo5, Yukihiro Shiraki1, Naoya Asai3, Masato Asai1, Masato Nagino2, Masahide Takahashi1,3

1Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan

2Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

3Division of Molecular Pathology, Center for Neurological Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

4Tumour Cell Biology Laboratory, The Francis Crick Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom

5Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan

Correspondence to:

Masahide Takahashi, email: mtakaha@med.nagoya-u.ac.jp

Keywords: skin carcinogenesis, CD109, TGF-β, p21, Nrf2

Received: May 16, 2016    Accepted: October 02, 2016    Published: October 14, 2016


CD109 is a glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed in several types of human cancers, particularly squamous cell carcinomas. We previously reported that CD109-deficient mice exhibit epidermal hyperplasia and chronic skin inflammation. Although we found that CD109 regulates differentiation of keratinocytes in vivo, the function of CD109 in tumorigenesis remains unknown. In this study, we investigated the role of CD109 in skin tumorigenesis using a two-stage carcinogenesis model in CD109-deficient mice with chronic skin inflammation. Immunohistochemical analysis revealed a higher level of TGF-β protein expression in the dermis of CD109-deficient mice than in that of wild-type mice. Additionally, immunofluorescence analysis showed that Smad2 phosphorylation and Nrf2 expression were enhanced in primary keratinocytes from CD109-deficient mice compared with in those from wild-type mice. Although no significant difference was found in conversion rates from papilloma to carcinoma between wild-type and CD109-deficient mice in the carcinogenesis model, we observed fewer and smaller papillomas in CD109-deficient mice than in wild-type mice. Apoptosis and DNA damage marker levels were significantly reduced in CD109-deficient skin compared with in wild-type skin at 24 h after 7, 12-dimethylbenz (α) anthracene treatment. Furthermore, mutation-specific PCR revealed that the mutation frequency of the H-ras gene was less in CD109-deficient skin than in wild-type skin in this model. These results suggest that CD109 deficiency suppresses skin tumorigenesis by enhancing TGF-β/Smad/Nrf2 pathway activity and decreasing the mutation frequency of the H-ras gene.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12653